Lv21
120 积分 2025-05-29 加入
Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma The NRG Oncology/RTOG 1112 Phase 3 Randomized Clinical Trial
22天前
已完结
Sintilimab plus bevacizumab combined with radiotherapy as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A multicenter, single-arm, phase 2 study
22天前
已完结
Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy
23天前
已完结
Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages
1个月前
已完结
BCLC strategy for prognosis prediction and treatment recommendations: The 2025 update
1个月前
已完结
Sintilimab Plus Axitinib for Advanced Fumarate Hydratase-Deficient Renal Cell Carcinoma: A Phase 2 Nonrandomized Clinical Trial
2个月前
已完结
Renal cell carcinoma
3个月前
已完结
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2025 Update
3个月前
已完结
Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitors and Subsequent Therapy for Renal Cell Carcinoma
3个月前
已完结
Sintilimab Plus Axitinib for Advanced Fumarate Hydratase-Deficient Renal Cell Carcinoma: A Phase 2 Nonrandomized Clinical Trial
3个月前
已完结
皖公网安备34019202002308
